Inventor · disambiguated record
Anjan Thakurta
Also filed as: THAKURTA ANJAN · THAKURTA ANJAN G · THAKURTA ANJAN GUHA
6 granted patents·11 pending applications·21 citations·filing 2015–2025
77Inventor score
Files withCELGENE CORP13AGIOS PHARMACEUTICALS INC1BRISTOL MYERS SQUIBB CO1CELEGENE CORP1ENGMAB SARL1
Top patents by PatentIndex Score
17 records- 0192US10137130B2Methods of treatment of malignanciesCELGENE CORP·Filed 2016·Granted Nov 27, 2018·9 cites·16 claims
- 0289US9587281B2Cereblon isoforms and their use as biomarkers for therapeutic treatmentCELGENE CORP·Filed 2015·Granted Mar 7, 2017·8 cites·31 claims
- 0378US12396995B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Aug 26, 2025·0 cites·34 claims
- 0478US2025352551A1Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2025·Application pending·0 cites
- 0576US11529339B2Combination therapy for the treatment of cancerCELGENE CORP·Filed 2019·Granted Dec 20, 2022·2 cites·21 claims
- 0668US11583536B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted Feb 21, 2023·0 cites·41 claims
- 0768US10034872B2Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodiesCELGENE CORP·Filed 2015·Granted Jul 31, 2018·2 cites·35 claims
- 0857US2020261434A1Idh1 inhibitors for the treatment of haematological malignancies and solid tumorsAGIOS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0957US2024228667A9Methods for Treating Multiple MyelomaCELGENE CORP·Filed 2022·Application pending·0 cites
- 1053US2023172923A1Methods of treating cytokine-related adverse eventsBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1152US2017362660A1Cereblon isoforms and their use as biomarkers for therapeutic treatmentCELGENE CORP·Filed 2017·Application pending·0 cites
- 1250US2024229156A1Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profilesCELGENE CORP·Filed 2022·Application pending·0 cites
- 1347US2023364230A1Combination therapy for cancerENGMAB SARL·Filed 2021·Application pending·0 cites
- 1447US2023255975A1Methods for treating cancer with combination therapiesCELGENE CORP·Filed 2021·Application pending·0 cites
- 1544US2023023070A1Therapy for the Treatment of CancerCELEGENE CORP·Filed 2020·Application pending·0 cites
- 1643US2018042930A1Methods of treatment of malignanciesCELGENE CORP·Filed 2017·Application pending·0 cites
- 1741US2017157103A1Methods of treating diffuse large b-cell lymphoma using 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →